INFLIXIMAB — CENTOCOR INC, approved 2025-02-28 (BLA103772).
323,142 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.